

Henry Chrystyn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7912591/publications.pdf>

Version: 2024-02-01

46
papers

2,109
citations

257101

24
h-index

233125

45
g-index

47
all docs

47
docs citations

47
times ranked

1605
citing authors

#	ARTICLE	IF	CITATIONS
1	Investigating the Accuracy of the Digihaler, a New Electronic Multidose Dry-Powder Inhaler, in Measuring Inhalation Parameters. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2022, 35, 166-177.	0.7	11
2	Gaining an insight into the importance of each inhalation manoeuvre parameter using altered patients'™ inhalation profiles. <i>Journal of Drug Delivery Science and Technology</i> , 2021, 61, 102181.	1.4	2
3	The dry powder inhaler features of the Easyhaler that benefit the management of patients. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 345-351.	1.0	9
4	Real-life inhaler adherence and technique: Time to get smarter!. <i>Respiratory Medicine</i> , 2019, 158, 24-32.	1.3	25
5	Real-life budesonide and formoterol dose emission from the medium and high strength fixed dosed combinations in a Spiromax® dry powder inhaler using inhalation profiles from patients with chronic obstructive pulmonary disease. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 139, 105059.	1.9	5
6	Use of inspiratory profiles from patients with chronic obstructive pulmonary disease (COPD) to investigate drug delivery uniformity and aerodynamic dose emission of indacaterol from a capsule based dry powder inhaler. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 134, 138-144.	1.9	10
7	Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT. <i>Health Technology Assessment</i> , 2019, 23, 1-146.	1.3	7
8	Relationship of Inhaled Corticosteroid Adherence to Asthma Exacerbations in Patients with Moderate-to-Severe Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1989-1998.e3.	2.0	44
9	Inhaler technique mastery and maintenance in healthcare professionals trained on different devices. <i>Journal of Asthma</i> , 2018, 55, 79-88.	0.9	18
10	Study of the Emitted Dose After Two Separate Inhalations at Different Inhalation Flow Rates and Volumes and an Assessment of Aerodynamic Characteristics of Indacaterol Onbrez Breezhaler® 150 and 300µg. <i>AAPS PharmSciTech</i> , 2018, 19, 251-261.	1.5	15
11	Systematic review of association between critical errors in inhalation and health outcomes in asthma and COPD. <i>Npj Primary Care Respiratory Medicine</i> , 2018, 28, 43.	1.1	63
12	Evaluation of inhaler technique and achievement and maintenance of mastery of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in adult patients with asthma: the Easy Low Instruction Over Time (ELIOT) study. <i>BMC Pulmonary Medicine</i> , 2018, 18, 107.	0.8	9
13	Device errors in asthma and COPD: systematic literature review and meta-analysis. <i>Npj Primary Care Respiratory Medicine</i> , 2017, 27, 22.	1.1	146
14	Effect of maximum inhalation flow and inhaled volume on formoterol drug deposition in-vitro from an Easyhaler® dry powder inhaler. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 104, 180-187.	1.9	19
15	Real life dose emission characterization using COPD patient inhalation profiles when they inhaled using a fixed dose combination (FDC) of the medium strength Symbicort® Turbuhaler®. <i>International Journal of Pharmaceutics</i> , 2017, 522, 137-146.	2.6	24
16	Inhaler Errors in the CRITIKAL Study: Type, Frequency, and Association with Asthma Outcomes. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 1071-1081.e9.	2.0	229
17	In vitro aerodynamic characteristics of aerosol delivered from different inhalation methods in mechanical ventilation. <i>Pharmaceutical Development and Technology</i> , 2017, 22, 844-849.	1.1	37
18	Comparison of serious inhaler technique errors made by device-naïve patients using three different dry powder inhalers: a randomised, crossover, open-label study. <i>BMC Pulmonary Medicine</i> , 2016, 16, 12.	0.8	28

#	ARTICLE	IF	CITATIONS
19	Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial. <i>Trials</i> , 2015, 16, 267.	0.7	20
20	Concept review of dry powder inhalers: correct interpretation of published data. <i>Multidisciplinary Respiratory Medicine</i> , 2015, 10, 36.	0.6	3
21	Effect of inhalation profile and throat geometry on predicted lung deposition of budesonide and formoterol (BF) in COPD: An in-vitro comparison of Spiromax with Turbuhaler. <i>International Journal of Pharmaceutics</i> , 2015, 491, 268-276.	2.6	46
22	Spiromax, a New Dry Powder Inhaler: Dose Consistency under Simulated Real-World Conditions. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2015, 28, 309-319.	0.7	52
23	Preference, satisfaction and critical errors with Genuair and Breezhaler inhalers in patients with COPD: a randomised, cross-over, multicentre study. <i>Npj Primary Care Respiratory Medicine</i> , 2015, 25, 15018.	1.1	27
24	Inhalation characteristics of asthma patients, COPD patients and healthy volunteers with the Spiromax® and Turbuhaler® devices: a randomised, cross-over study. <i>BMC Pulmonary Medicine</i> , 2015, 15, 47.	0.8	43
25	The Inhalation Characteristics of Patients When They Use Different Dry Powder Inhalers. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2015, 28, 35-42.	0.7	84
26	Indacaterol Determination in Human Urine: Validation of a Liquid-Liquid Extraction and Liquid Chromatography-Tandem Mass Spectrometry Analytical Method. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2015, 28, 202-210.	0.7	7
27	Impact of patients' satisfaction with their inhalers on treatment compliance and health status in COPD. <i>Respiratory Medicine</i> , 2014, 108, 358-365.	1.3	125
28	Aerodynamic dose emission characteristics of dry powder inhalers using an Andersen Cascade Impactor with a mixing inlet: The influence of flow and volume. <i>International Journal of Pharmaceutics</i> , 2013, 455, 213-218.	2.6	15
29	Clarifying the dilemmas about inhalation techniques for dry powder inhalers: integrating science with clinical practice. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2012, 21, 208-213.	2.5	65
30	The Effect of Dose on the Characterization of Aerodynamic Particle-size Distributions of Beclomethasone Dipropionate Metered-dose Inhalers. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 50, 1081-1085.	1.2	6
31	Salbutamol relative lung and systemic bioavailability of large and small spacers. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 60, 1609-1613.	1.2	13
32	Evaluation of supercritical fluid engineered budesonide powder for respiratory delivery using nebulisers. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 61, 1625-1630.	1.2	11
33	Choosing inhaler devices for people with asthma: Current knowledge and outstanding research needs. <i>Respiratory Medicine CME</i> , 2010, 3, 125-131.	0.1	20
34	Aerodynamic characteristics of a dry powder inhaler at low inhalation flows using a mixing inlet with an Andersen Cascade Impactor. <i>European Journal of Pharmaceutical Sciences</i> , 2010, 39, 348-354.	1.9	31
35	Choosing inhaler devices for people with asthma: Current knowledge and outstanding research needs. <i>Respiratory Medicine</i> , 2010, 104, 1237-1245.	1.3	146
36	Inhaled corticosteroids for asthma: impact of practice level device switching on asthma control. <i>BMC Pulmonary Medicine</i> , 2009, 9, 1.	0.8	111

#	ARTICLE	IF	CITATIONS
37	Not all asthma inhalers are the same: factors to consider when prescribing an inhaler. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2009, 18, 243-249.	2.5	104
38	The Potential of a 2Tone Trainer To Help Patients Use Their Metered-Dose Inhalers. Chest, 2007, 131, 1776-1782.	0.4	76
39	Can all patients with COPD use the correct inhalation flow with all inhalers and does training help?. Respiratory Medicine, 2007, 101, 2395-2401.	1.3	192
40	Closer to an Ideal Inhaler with the Easyhaler. Clinical Drug Investigation, 2006, 26, 175-183.	1.1	29
41	Emitted dose estimates from Seretide® Diskus® and Symbicort® Turbuhaler® following inhalation by severe asthmatics. International Journal of Pharmaceutics, 2006, 316, 131-137.	2.6	79
42	Methods to determine lung distribution of inhaled drugs - could gamma scintigraphy be the gold standard?. British Journal of Clinical Pharmacology, 2000, 49, 525-528.	1.1	17
43	The Diskus Inhaler. Clinical Drug Investigation, 1999, 18, 287-296.	1.1	6
44	Steady-state clearance rates of warfarin and its enantiomers in therapeutically dosed patients. , 1997, 9, 13-16.		12
45	Standards for Bioequivalence of Inhaled Products. Clinical Pharmacokinetics, 1994, 26, 1-6.	1.6	32
46	Measurement of the (R)- and (S)-isomers of warfarin in patients undergoing anticoagulant therapy. Chirality, 1992, 4, 488-493.	1.3	28